

XP-002133615

AN - 1991-262316 [36]

AP - JP19890309900 19891129; [Previous Publ. JP3170498]; JP19890309900 19891129

CPY - TEIK

DC - B04

FS - CPI

IC - A61K37/02 ; A61K38/00 ; A61P37/04 ; C07K7/06 ; C07K99/00

MC - B04-C01B B12-A01 B12-A06

M1 - [01] H1 H100 H101 H181 H182 H4 H401 H481 H8 J0 J011 J012 J1 J171 J172
M280 M312 M313 M314 M315 M321 M331 M332 M333 M340 M342 M343 M349 M381
M391 M423 M510 M520 M530 M540 M620 M710 M903 M904 P434 V902 V912 V921;
9136-15401-N

PA - (TEIK) TEIKOKU HORMONE MFG CO LTD

PN - JP3002213B2 B2 20000124 DW200009 C07K7/06 006pp

- JP3170498 A 19910724 DW199136 006pp

PR - JP19890309900 19891129

XA - C1991-113780

XIC - A61K-037/02 ; A61K-038/00 ; A61P-037/04 ; C07K-007/06 ; C07K-099/00

AB - J03170498 Peptide contg. amino acid sequence of formula

Thr-Asp-Asp-Thr-Ala-Ile-Val-Leu-Leu-Lys (I) is new. Also new is the agent contg. (I) having Interleukin-1 (IL-L) activity.

- The peptide is pred. by chemical method such as solid phase or liq. phase method, by biochemical method using synthesized DNA, or by extraction of salivary gland hormone derived from parotid gland of animals or its subunit. USE/ADVANTAGE- The peptide has short amino acid sequence, increasing activity of selective antibody prodn, and proliferation activity of thymus cells in the presence of Con A. The peptide can be used as IL-1 substance with little side-effect. The agent contg. IL-1 can increase vaccine effect, host cell defence ability, and improve immuno deficiency of the cancer patients on chemotherapy or on X-ray treatment. The agent can be formulated into tablets, granules, powders, capsules for oral admin, sols, frozen drying agent for injection, cataplast, ointment for percutaneous admin, eye drops etc., (6pp Dwg.No. 0/0)

CN - 9136-15401-N

IW - NEW PEPTIDE INTERLEUKIN ACTIVE INCREASE ANTIBODY PRODUCE VACCINE EFFECT DECREASE IMMUNODEFICIENCY CANCER PATIENT

IKW - NEW PEPTIDE INTERLEUKIN ACTIVE INCREASE ANTIBODY PRODUCE VACCINE EFFECT DECREASE IMMUNODEFICIENCY CANCER PATIENT

NC - 001

OPD - 1989-11-29

ORD - 1991-07-24

PAW - (TEIK) TEIKOKU HORMONE MFG CO LTD

TI - New peptide with interleukin-1 activity - for increasing antibody

prodn., vaccine effect and for decreasing immunodeficiency in cancer patients